Oppenheimer Lifts Acadia Price Target to $23; EMA Gives Trofinetide Negative Vote
Oppenheimer raised Acadia’s price target by $2 to $23 and maintained a Perform rating for 2026. The EMA’s CHMP issued a negative trend vote on the MAA for trofinetide in Rett syndrome, prompting Acadia to request re-examination as over 1,000 patients currently receive therapy worldwide.
1. Oppenheimer Raises Price Target
Oppenheimer boosted its price target on Acadia by $2 to $23 while maintaining a Perform rating and a balanced outlook for 2026 after direct discussions with management and investors.
2. EMA CHMP Issues Negative Trend Vote
The EMA’s Committee for Medicinal Products for Human Use delivered a negative trend vote on the marketing authorization application for trofinetide in Rett syndrome, prompting Acadia to seek re-examination once the formal opinion is adopted later this month.
3. Trofinetide Clinical Adoption
Trofinetide is currently administered to over 1,000 patients across the U.S., Canada, and Israel, with clinical study outcomes and real-world data demonstrating efficacy in both newly diagnosed toddlers and adults with chronic symptoms.
4. Strategic Pipeline and AI Focus
Acadia continues to advance its biopharmaceutical pipeline for neurological and rare diseases, leveraging precision science and AI-driven analytics alongside its FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome.